Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

Abroad (travel likely)RecruitingPHASE2

Conditions

HCC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Contact: Study coordinator (Lei Zhao) · drzhaolei@hotmail.com · 053167626368
Contact: Principal Investigator (Lei Zhao)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma · Conversion Therapy

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Lanzhou, China · Guangzhou, China

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bengbu, China · Hefei, China

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Hepato Cellular Carcinoma (HCC) · Intrahepatic Cholangiocarcinoma

Abroad (travel likely)Recruiting

Amiens, France · Angers, France